I wrote this many months ago so I could try to figure out exactly where the lipid nanoparticles may distribute over what time frame, when injected either through intravenous or intramuscular pathways. It’s a personal assessment that has not been peer reviewed for error, so please be cautious and do your own due diligence on the work if you decide to use points from it. I had to interpret a Japanese version of the document combined with an EMA assessment, since I was having trouble locating the English PDF at the time, so sorry for any strange wording as a result. I have since found versions of both PDFs, copies below: